Ernexa Therapeutics, Inc. engages in the provision of cell engineering therapies. The company is headquartered in Cambridge, Massachusetts and currently employs 6 full-time employees. The firm is focused on using cutting-edge gene-editing tools to deliver safe off-the-shelf cell therapies for the treatment of advanced solid tumors. Its Pipeline includes ERNA-101, and ERNA-102. Its core technology utilizes engineer allogenic-induced pluripotent stem cells (iPSCs) to express genes of interest and to efficiently differentiate these cells into mesenchymal stem cells (iMSCs). The firm seeks to capitalize on the intrinsic tumor-homing ability of MSCs to slip through the tumor’s defenses and to deliver potent pro-inflammatory factors directly to the tumor microenvironment (TME), thus unleashing potent anti-cancer immune responses. The firm is focused on developing iPSC-derived iMSC that express critical factors, such as pro-inflammatory cytokines.
Follow-Up Questions
Ernexa Therapeutics Inc의 CEO는 누구입니까?
Mr. Sanjeev Luther은 2024부터 회사에 합류한 Ernexa Therapeutics Inc의 President입니다.
ERNA 주식의 가격 성능은 어떻습니까?
ERNA의 현재 가격은 $1.31이며, 전 거래일에 decreased 1.24% 하였습니다.
Ernexa Therapeutics Inc의 주요 사업 주제나 업종은 무엇입니까?
Ernexa Therapeutics Inc은 Biotechnology 업종에 속하며, 해당 부문은 Health Care입니다
